Dataset Information

Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation.

ABSTRACT: The use of nanotechnology has the potential to revolutionize the detection and treatment of cancer. Developments in protein engineering and materials science have led to the emergence of new nanoscale targeting techniques, which offer renewed hope for cancer patients. While several nanocarriers for medicinal purposes have been approved for human trials, only a few have been authorized for clinical use in targeting cancer cells. In this review, we analyze some of the authorized formulations and discuss the challenges of translating findings from the lab to the clinic. This study highlights the various nanocarriers and compounds that can be used for selective tumor targeting and the inherent difficulties in cancer therapy. Nanotechnology provides a promising platform for improving cancer detection and treatment in the future, but further research is needed to overcome the current limitations in clinical translation.

SUBMITTER: Chehelgerdi M

PROVIDER: S-EPMC10561438 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation.

Chehelgerdi Mohammad M Chehelgerdi Matin M Allela Omer Qutaiba B OQB Pecho Renzon Daniel Cosme RDC Jayasankar Narayanan N Rao Devendra Pratap DP Thamaraikani Tamilanban T Vasanthan Manimaran M Viktor Patrik P Lakshmaiya Natrayan N Saadh Mohamed J MJ Amajd Ayesha A Abo-Zaid Mabrouk A MA Castillo-Acobo Roxana Yolanda RY Ismail Ahmed H AH Amin Ali H AH Akhavan-Sigari Reza R

Molecular cancer 20231009 1

The use of nanotechnology has the potential to revolutionize the detection and treatment of cancer. Developments in protein engineering and materials science have led to the emergence of new nanoscale targeting techniques, which offer renewed hope for cancer patients. While several nanocarriers for medicinal purposes have been approved for human trials, only a few have been authorized for clinical use in targeting cancer cells. In this review, we analyze some of the authorized formulations and d ...[more]

PMID: 37814270

Similar Datasets

Project description:BackgroundHeart failure is a major public health concern, affecting 6.7 million Americans. An estimated 16% of emergency department (ED) patients with acute heart failure (AHF) are discharged home. Our Get with the Guidelines in Emergency Department Patients with Heart Failure (GUIDED-HF) toolkit aims to improve AHF self-care and facilitate safer transitions in care for these patients. We describe implementation barriers and facilitators, and the selection and refinement of implementation strategies, to facilitate future GUIDED-HF implementation.MethodsA mixed-methods cross-sectional observational study was conducted in four United States EDs in two diverse healthcare systems in the Pacific West and Midwest. Data were collected using a survey and interviews with ED providers, nurses, and leaders. The survey assessed the ED context using the context scale of the Organizational Readiness to Change Assessment (ORCA). The Consolidated Framework for Implementation Research informed interviews. Quantitative data were summarized using medians (interquartile ranges) or percentages (frequencies). Wilcoxon rank-sum tests and Kruskal-Wallis tests were used to assess differences in the healthcare system and profession. Qualitative data were analyzed and summarized using rapid qualitative analysis. Convergence of quantitative and qualitative data was used to inform specific refining of implementation strategies to the local context (e.g., who should serve as champions, how best practice alerts should be implemented).ResultsParticipants were predominately white (76%) with median (IQR) age 37.0 (32.0, 41.0). ED leaders/administrators, providers, and nurses comprised 15%, 55%, and 29% of participants, respectively. Sites reported an ORCA context scale score of 3.7 [3.4, 4.0] (scale of 1 = strongly disagree to 5 = strongly agree). Comparison of scores by profession showed a significant difference in the context score among providers (3.9 [3.5, 4.0]), leaders (3.7 [3.5, 4.0]), and nurses (3.6 [3.0, 3.9]) (p = 0.048). Qualitative data indicated implementation barriers (e.g., resource limitations, patient health literacy), facilitators (e.g., GUIDED-HF is patient-centric; site and intervention congruent values, norms, and goals), and site-specific needs due to contextual factors (e.g., education needs, feedback mechanisms, champions).ConclusionsSpecific determinants of implementation exist in ED settings and require the refining of implementation strategies to overcome site-specific barriers and enhance facilitators.Trial registrationn/a.

Dataset Information

Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation.

Publications

Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets